Thoratec Announces HeartMate 3 CE Mark Trial Met Primary Endpoint
September 27, 2015 at 16:19 PM EDT
Thoratec Corporation (NASDAQ: THOR) today announced results from the HeartMate 3™ CE Mark trial. HeartMate 3 met the primary ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.